Oncoinvent ASA
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
OCIN | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- NO0010779341 (+1 more)
- LEI:
- 54930076H5GUZRMSNR39
- Country:
- Norway
- Address:
- Gullhaugveien 7, 0484 Oslo
- Website:
- https://www.oncoinvent.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Oncoinvent ASA is a clinical-stage biotechnology company dedicated to developing innovative radiopharmaceutical products for cancer treatment. The company's core focus is on direct alpha therapy. Its lead product candidate, Radspherin®, is an alpha-emitting therapeutic designed for treating cancers within the peritoneal cavity, such as metastatic colorectal and ovarian cancers. The technology utilizes biodegradable, inorganic microparticles as carriers for alpha-emitters, enabling the delivery of high-power, short-range radiation directly to tumors. This approach ensures regional retention of the effective radiation dose while minimizing systemic exposure. Oncoinvent is actively advancing its product pipeline through clinical trials, including a Phase 2 program for Radspherin® in ovarian cancer patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-12 07:00 |
Share Issue/Capital Change
Oncoinvent ASA: EX. SUBSCRIPTION RIGHTS IN RIGHTS ISSUE TODAY
|
English | 515 bytes | ||
| 2025-11-11 18:16 |
Share Issue/Capital Change
Oncoinvent ASA: Terms of the underwritten Rights Issue
|
English | 11.4 KB | ||
| 2025-11-11 17:32 |
Share Issue/Capital Change
Oncoinvent ASA: Updated Key Information related to the contemplated Rights Issue
|
English | 11.5 KB | ||
| 2025-11-03 12:55 |
Report Publication Announcement
Reminder: Invitation to presentation of Q3 2025 company update on November 4[th…
|
English | 3.3 KB | ||
| 2025-11-03 12:15 |
Major Shareholding Notification
NOTIFICATION OF MAJOR HOLDINGS - Attachment: Notification of major holding Linc…
|
English | 279.0 KB | ||
| 2025-11-03 12:15 |
Major Shareholding Notification
NOTIFICATION OF MAJOR HOLDINGS
|
English | 266 bytes | ||
| 2025-11-03 11:49 |
Major Shareholding Notification
Disclosure of large shareholding
|
English | 1.0 KB | ||
| 2025-11-03 10:09 |
Major Shareholding Notification
Flaggemelding
|
Norwegian | 631 bytes | ||
| 2025-11-03 09:39 |
Major Shareholding Notification
Flaggemelding – Hadean Ventures AS / HVentures AB – Oncoinvent AS (ONCIN)
|
Norwegian | 1.7 KB | ||
| 2025-11-03 08:55 |
Director's Dealing
Mandatory notification of trade - Attachment: PDMR_Attachment_allocation_of_con…
|
English | 226.4 KB | ||
| 2025-11-03 08:55 |
Director's Dealing
Mandatory notification of trade - Attachment: 2025_11_03_vederlags_aksjer.pdf
|
English | 34.9 KB | ||
| 2025-11-03 08:55 |
Director's Dealing
Mandatory notification of trade
|
English | 2.4 KB | ||
| 2025-10-31 08:30 |
Board/Management Information
Oncoinvent appoints Dr. Ramzi Amri as new CFO - Attachment: 251031_Oncoinvent_C…
|
English | 167.8 KB | ||
| 2025-10-31 08:30 |
Board/Management Information
Oncoinvent appoints Dr. Ramzi Amri as new CFO
|
English | 4.9 KB | ||
| 2025-10-29 22:17 |
Report Publication Announcement
Financial calendar
|
English | 683 bytes |
Automate Your Workflow. Get a real-time feed of all Oncoinvent ASA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oncoinvent ASA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oncoinvent ASA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
%20Inc./other/Mind_Medicine_MindMed_Inc.-logo.png){kind=logo}